- Home
- NOEM vs ASMB Comparison
NOEM vs ASMB Comparison
Compare NOEM & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOEM
- ASMB
- Stock Information
- Founded
- NOEM 2021
- ASMB 2005
- Country
- NOEM United States
- ASMB United States
- Employees
- NOEM N/A
- ASMB N/A
- Industry
- NOEM
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- NOEM
- ASMB Health Care
- Exchange
- NOEM Nasdaq
- ASMB Nasdaq
- Market Cap
- NOEM 94.6M
- ASMB 84.5M
- IPO Year
- NOEM 2024
- ASMB 2010
- Fundamental
- Price
- NOEM $9.92
- ASMB $9.39
- Analyst Decision
- NOEM
- ASMB Strong Buy
- Analyst Count
- NOEM 0
- ASMB 3
- Target Price
- NOEM N/A
- ASMB $33.00
- AVG Volume (30 Days)
- NOEM 126.9K
- ASMB 29.1K
- Earning Date
- NOEM 01-01-0001
- ASMB 05-07-2025
- Dividend Yield
- NOEM N/A
- ASMB N/A
- EPS Growth
- NOEM N/A
- ASMB N/A
- EPS
- NOEM 0.00
- ASMB N/A
- Revenue
- NOEM N/A
- ASMB $28,520,000.00
- Revenue This Year
- NOEM N/A
- ASMB $10.82
- Revenue Next Year
- NOEM N/A
- ASMB N/A
- P/E Ratio
- NOEM $36,128.66
- ASMB N/A
- Revenue Growth
- NOEM N/A
- ASMB 298.16
- 52 Week Low
- NOEM $9.78
- ASMB $9.04
- 52 Week High
- NOEM $10.78
- ASMB $19.93
- Technical
- Relative Strength Index (RSI)
- NOEM N/A
- ASMB 30.15
- Support Level
- NOEM N/A
- ASMB $10.70
- Resistance Level
- NOEM N/A
- ASMB $11.78
- Average True Range (ATR)
- NOEM 0.00
- ASMB 0.58
- MACD
- NOEM 0.00
- ASMB -0.05
- Stochastic Oscillator
- NOEM 0.00
- ASMB 12.77
About NOEM CO2 Energy Transition Corp. Common Stock
CO2 Energy Transition Corp is a blank check company.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.